WASHINGTON (dpa-AFX) - Incyte Corp. (INCY) reported final results from the Phase I clinical trial for its oral indoleamine dioxygenase-1, or IDO1 inhibitor, INCB024360. The company said the results from the first Phase I study were encouraging.
The Phase I study of INCB024360 is an open-label, single-agent dose-escalation trial in 52 patients with advanced malignancies. Using two independent pharmacodynamic assays, IDO1 inhibition was observed in all patients receiving the compound. The company said treatment with a number of doses of INCB024360 resulted in greater than 90 percent inhibition of IDO1 activity, which were well tolerated with no maximum tolerated dose established. The most common grade 1 or 2 adverse events were fatigue and gastrointestinal disturbances, and the most common grade 3 or 4 adverse events were abdominal pain, hypokalemia and fatigue.
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de